Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.

Mohammad A., et al, (2023) Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants. Available at MDPI

Zabala-Findlay A., et al, (2023) Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease: Systematic Review and Meta-Analysis. Available at Cells.

Kondak C., et al, (2023) Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice. Available at International Journal of Molecular Sciences.

Al-Hilaly, YK, et al (2022) Solid-state NMR of paired helical filaments formed by the core tau fragment tau (297-391). Available at Frontiers in Neuroscience.

Kondak, C., et al, (2022) Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine Available at Journal of Neurochemistry